<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="40">
  <stage>Registered</stage>
  <submitdate>19/07/2005</submitdate>
  <approvaldate>19/07/2005</approvaldate>
  <actrnumber>ACTRN12605000025639</actrnumber>
  <trial_identification>
    <studytitle>The MAX study</studytitle>
    <scientifictitle>The MAX Study: A randomised phase II/III study to determine the relative toxicity of Mitomycin C, Avastin and X eloda in patients with untreated metastatic colorectal cancer, and to compare the effects of Mitomycin C, Avastin and Xeloda in patients with untreated metastatic colorectal cancer on progression-free survival</scientifictitle>
    <utrn />
    <trialacronym>MAX</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR561</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic colorectal cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The MAX study is a multi-centre, stratified, randomised, phase II/III study that aims to compare the safety and efficacy of the combination of capecitabine and bevacizumab and the combination of capecitabine, Mitomycin C (MMC) and bevacizumab, with that of capecitabine monotherapy in patients with previously untreated metastatic colorectal cancer.  Treatment will continue until disease progression, unless there is unacceptable toxicity or either the patient or physician requests cessation of treatment.</interventions>
    <comparator>.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression free survival</outcome>
      <timepoint>Measured after 450 patients have completed 1 year of follow-up</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment related toxicity</outcome>
      <timepoint>Measured after 450 patients have completed 1 year of follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment response</outcome>
      <timepoint>Measured after 450 patients have completed 1 year of follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Measured after 450 patients have completed 1 year of follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Symptoms of  disease, treatment and quality of life</outcome>
      <timepoint>Measured after 450 patients have completed 1 year of follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cost of therapy and assessment of gain in quality adjusted progression free survival</outcome>
      <timepoint>Measured after 450 patients have completed 1 year of follow-up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>a)Histological diagnosis of metastatic colorectal cancer. b)Any patient in whom the investigator considers capecitabine monotherapy appropriate. c)Evaluable or non-evaluable disease as assessed by CT scan. d)ECOG performance status 0, 1 or 2.  Patients with PS2 should have serum albumin &gt;30 g/L. e)No prior chemotherapy agents or anti-angiogenic biological agents (e.g. anti VEGF) for treatment of advanced disease. Adjuvant chemotherapy (including antiangiogenic therapy) which was completed &gt; 6 months ago is allowed. f)Adequate bone marrow function with platelets &gt; 100 X 109/l; neutrophils &gt; 1.5 X 109/l. g)Adequate renal function, with calculated creatinine clearance &gt;30 ml/min (Cockcroft and Gault). For patients with creatinine clearance &lt;50 ml/min the starting dose of capecitabine may not be greater than 2000 mg/m2/d (See section 6.1) h)Adequate hepatic function with serum total bilirubin &lt; 1.5 X upper limit of normal range. i)Life expectancy of at least 12 weeks. j)No concurrent uncontrolled medical conditions. k)No previous malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix or any other cancer treated with curative intent &gt;2 years previously without evidence of relapse. l)Women and partners of women of childbearing potential must agree to use adequate contraception. m)Written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation made from a central site</concealment>
    <sequence>Random allocation sequence generated by ClinTrials software with adaptive minimisation. Stratification by age (=/&gt;65y vs &lt;65y), WHO Performance status and Institution</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>27/06/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>450</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australian Gastro-Intestinal Trials Group (AGITG)</primarysponsorname>
    <primarysponsoraddress>88 Mallett St
Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Roche Products Australia - educational grant</fundingname>
      <fundingaddress>4-10 Inman Rd
Dee Why NSW 2099</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>NHMRC Clinical Trials Centre</sponsorname>
      <sponsoraddress>88 Mallett St
Camperdown NSW 2050</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nepean Cancer Care Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Lismore Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Niall Tebbutt</name>
      <address>Austin Hospital
Heidelberg VIC 3084</address>
      <phone>+61 3 9496 3217</phone>
      <fax>+61 3 9457 6698</fax>
      <email>niall.tebbutt@ludwig.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Burcu Cakir</name>
      <address>NHMRC Clinical Trials Centre
Locked bag 77
Camperdown NSW 2050</address>
      <phone>+61 2 95625000</phone>
      <fax>+61 2 95625094</fax>
      <email>max@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>